OTC Switch Sponsors Should Study Up On FDA Procedure, FDAer Suggests
This article was originally published in The Tan Sheet
Executive Summary
OTC drug submission sponsors should be up to speed on all of FDA's application procedures when developing a switch program, according to OTC Division Medical Officer Andrea Leonard-Segal, MD
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning